Pe­ter Thiel-backed ATAI launch­es new Salvia-fo­cused biotech; Pur­due bank­rupt­cy tri­al ex­pect­ed to be­gin to­day — re­port

ATAI Life Sci­ences, the Pe­ter Thiel-backed um­brel­la de­vel­op­er of psy­che­delics and oth­er drugs for men­tal health con­di­tions, launched a new port­fo­lio com­pa­ny Thurs­day.

The new out­fit is called Re­vix­ia Life Sci­ences, and its mis­sion is to bring the main ac­tive in­gre­di­ent in Salvia to the clin­ic for treat­ment-re­sis­tant de­pres­sion, sub­stance use dis­or­der and pain, ATAI an­nounced Thurs­day morn­ing. The in­gre­di­ent in ques­tion is called Salvi­norin A, and Re­vix­ia says it’s a non-ni­troge­nous ag­o­nist of the kap­pa-opi­oid re­cep­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA